Evidence map›Paper›PMID 36322005›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2023

Conditioning Regimens are Associated with Distinct Patterns of Microbiota Injury in Allogeneic Hematopoietic Cell Transplantation.

Roni Shouval, Nicholas R Waters, Antonio L C Gomes, Corrado Zuanelli Brambilla, Teng Fei, Sean M Devlin, Chi L Nguyen, Kate A Markey, Anqi Dai, John B Slingerland and 17 more

Open access · greenAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
6.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 42 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Upper and Lower Respiratory Tract Compartmentalization in Pediatric Stem Cell Transplantation.American journal of respiratory cell and molecular biology · 2026
    Article
  5. Observational
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Gut microbiota and acute graft-versus-host disease.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025
    Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Updated perspectives on the contribution of the microbiome to the pathogenesis of mucositis using the MASCC/ISOO framework.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 5 institutions in 4 countries.

Roni ShouvalAdult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-9827-8032
Nicholas R WatersDepartment of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-9035-2143
Antonio L C GomesDepartment of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-3790-3724
Corrado Zuanelli BrambillaAdult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-6396-2990
Teng FeiDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-7888-1715
Sean M DevlinDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-6801-720X
Chi L NguyenDepartment of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-8345-3563
Kate A MarkeyAdult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-7064-2362
Anqi DaiDepartment of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-3106-4624
John B SlingerlandDepartment of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-6574-9499
Annelie G ClurmanDepartment of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-8299-6734
Emily FontanaInfectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-9060-5382
Luigi A AmorettiInfectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-4625-5119
Roberta J WrightInfectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-5299-0024
Tobias M HohlDepartment of Medicine, Weill Cornell Medical College, New York, New York.ORCID 0000-0002-9097-5412
Ying TaurDepartment of Medicine, Weill Cornell Medical College, New York, New York.ORCID 0000-0002-6601-8284
Anthony D SungDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0003-3765-641X
Daniela WeberDepartment of Internal Medicine, University Medical Center, University of Regensburg, Regensburg, Germany.ORCID 0000-0003-3833-6311
Daigo HashimotoDepartment of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan.ORCID 0000-0001-9489-9704
Takanori TeshimaDepartment of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan.ORCID 0000-0002-0941-271X
Nelson J ChaoDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0001-6725-7220
Ernst HollerDepartment of Internal Medicine, University Medical Center, University of Regensburg, Regensburg, Germany.ORCID 0000-0003-2295-2187
Michael ScordoAdult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-9484-0240
Sergio A GiraltAdult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-1944-5053
Miguel-Angel PeralesAdult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-5910-4571
Jonathan U Peled *Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-4029-7625
Marcel R M van den Brink *Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-0696-4401
Memorial Sloan Kettering Cancer Center · USDuke Medical Center · USHokkaido University · JPUniversity Hospital Regensburg · DEUniversity of Siena · IT

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
T LYMPHOCYTE SUBSET FUNCTION POST-TRANSPLANTATIONP01CA023766 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI PERALES, MIGUEL-ANGEL · 1985 to 2023
$59.0M
Thymic and Peripheral Aspects of T Cell Aging and RejuvenationP01AG052359 · NIA · UNIVERSITY OF ARIZONA · PI Lauren Ilyse Richie EHRLICH · 2017 to 2026
$23.5M
The role of intestinal microbiota in graft-versus-host diseaseR01CA228308 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Philip L Lorenzi, Marcel R M van den Brink · 2018 to 2026
$5.2M
The role of autophagy gene Atg16L1 in allogeneic hematopoietic stem cell transplantation - Resubmission - 1R01HL123340 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CADWELL, KEN HASHIGIWA, VAN DEN BRINK, MARCEL R M · 2015 to 2022
$5.2M
Third-party “off the shelf” mature or precursor CAR T cells to prevent or treat malignant relapse after allo HCTR01HL147584 · NHLBI · SLOAN-KETTERING INST CAN RESEARCH · PI VAN DEN BRINK, MARCEL R M · 2019 to 2022
$2.7M
The role of intestinal microbiota in graft-versus-host diseaseR01CA228358 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI VAN DEN BRINK, MARCEL R M · 2018 to 2022
$2.6M
Prebiotics to Optimize the Microbiota and Improve Outcomes of AllogeneicHematopoietic Stem Cell TransplantationR01HL151365 · NHLBI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI SUNG, ANTHONY · 2020 to 2024
$1.8M
Microbiota mechanisms and biomarkers in GVHDK08HL143189 · NHLBI · SLOAN-KETTERING INST CAN RESEARCH · PI PELED, JONATHAN · 2019 to 2023
$858k
The mycobiota, bone marrow transplantation, and clinical outcomesR21AI156157 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI HOHL, TOBIAS M · 2021 to 2022
$487k
NCI NIH HHS P01 CA023766NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA228308NCI NIH HHS R01 CA228358NHLBI NIH HHS K08 HL143189NHLBI NIH HHS R01 HL123340NHLBI NIH HHS R01 HL147584NHLBI NIH HHS R01 HL151365NIAID NIH HHS R21 AI156157NIA NIH HHS P01 AG052359
6 · The paper itself

Abstract

purposeThe gut microbiota is subject to multiple insults in allogeneic hematopoietic cell transplantation (allo-HCT) recipients. We hypothesized that preparative conditioning regimens contribute to microbiota perturbation in allo-HCT. EXPERIMENTAL

designThis was a retrospective study that evaluated the relationship between conditioning regimens exposure in 1,188 allo-HCT recipients and the gut microbiome. Stool samples collected from 20 days before transplantation up to 30 days after were profiled using 16S rRNA sequencing. Microbiota injury was quantified by changes in α-diversity.

resultsWe identified distinct patterns of microbiota injury that varied by conditioning regimen. Diversity loss was graded into three levels of conditioning-associated microbiota injury (CMBI) in a multivariable model that included antibiotic exposures. High-intensity regimens, such as total body irradiation (TBI)-thiotepa-cyclophosphamide, were associated with the greatest injury (CMBI III). In contrast, the nonmyeloablative regimen fludarabine-cyclophosphamide with low-dose TBI (Flu/Cy/TBI200) had a low-grade injury (CMBI I). The risk of acute GVHD correlated with CMBI degree. Pretransplant microbial compositions were best preserved with Flu/Cy/TBI200, whereas other regimens were associated with loss of commensal bacteria and expansion of Enterococcus.

conclusionsOur findings support an interaction between conditioning at the regimen level and the extent of microbiota injury.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationMicrobiotaCyclophosphamideHumansRetrospective StudiesRNA, Ribosomal, 16STransplantation ConditioningTransplantation, HomologousCyclophosphamideRNA, Ribosomal, 16S

Identifiers

PMID36322005
PMCPMC9812902
OpenAlexW4307965815

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.